Intent to Sole Source Olsteoarthritis Biomarker Protocol

Added: Feb 02, 2015 12:12 pm The VA Office of Research and Development, Salt Lake City VA Medical Center, Research Department intends to negotiate on a sole source basis with contractor Artialis pursuant to FAR 6.302-1; for services in support of a VA approved research project. This notice of intent is not a request for competitive proposals, however; any responsible source who believes it is capable of meeting the requirement may submit a capability statement to the contracting office within 5 days of this posting. Interest/capability statements may be sent to Keith Costantino at keith.costantino@va.gov. No telephone responses will be accepted. A determination not to compete the proposed requirement based upon the responses to this notice is solely within the discretion of the Government. A description of the required services are as follows: The VA Salt Lake City research department requires the services of Artialis, to provide biomarker assay testing for the Salt Lake City research departments double blinded clinical trial for knee osteoarthritis patients. The study requirements consist of 160 patients being evaluated by the VA at Baseline, 12 weeks, 24 weeks and 48 weeks. Biomarker tests will be performed at each interval by the contractor. The biomarkers will be CTXII, Coll2-1 (a degradation produce to type II collagen whose concentration increases in osteoarthritis disease, consequently to the cartilage degradation) and Coll2-1-NO2 (the nitrated form of Coll2-1, a marker of the inflammatory process related to the cartilage degradation) in urine and serum, and s-COMP in serum.